Changes to This Summary (02/18/2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added American Cancer Society as reference 2.
Added text to state that oral isotretinoin use may be useful as a chempreventive agent in xeroderma pigmentosum and other hereditary skin cancer syndromes, including basal cell nevus syndrome (BCNS), Rombo syndrome, and epidermodysplasia verruciformis (cited Otley et al. as reference 211 and level of evidence [oral isotretinoin for BCNS, Rombo syndrome, epidermodysplasia verruciformis] 5).
Added PTEN and Cowden syndrome as a new subsection.
Added text about a study of 36 sebaceous lesions that included sebaceous carcinomas, sebaceous adenomas, and sebaceomas that suggests that routine screening of sebaceous lesions by immunohistochemistry may be useful in identification of individuals with Lynch syndrome (cited Plocharczyk et al. as reference 17).
Added text about a study that focused on 68 minor children of melanoma survivors that demonstrated that while overall rates of sun-protective behavior were high (near 80%), the rates of sunburn were also high (49%); the authors concluded that multiple methods of sun-protective behavior are warranted in these individuals (cited Glenn et al. as reference 22).
This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.